These innovative molecules represent a significant leap in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://blanchevllt647134.ambien-blog.com/45877771/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide